During the past decade, Stanford University conducted 43 clinical trials. In the 10-year time frame, 43 clinical trials started and 4 clinical trials were completed, i.e. on average, 9.3% percent of trials that started reached the finish line to date. In the past 5 years, 32 clinical trials started and 4 clinical trials were completed. i.e. 12.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Stanford University" #1 sponsor was "Stanford University" with 14 trials, followed by "Krystal Biotech, Inc." with 3 trials sponsored, "Phoenix Tissue Repair, Inc." with 3 trials sponsored, "Zimmer Biomet" with 2 trials sponsored and "Abeona Therapeutics, Inc" with 2 trials sponsored. Other sponsors include 21 different institutions and companies that sponsored additional 31 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Stanford University" #1 collaborator was "Stanford University" with 4 trials as a collaborator, "University of Minnesota" with 3 trials as a collaborator, "Mayo Clinic" with 2 trials as a collaborator, "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)" with 2 trials as a collaborator and "University of California, San Francisco" with 2 trials as a collaborator. Other collaborators include 36 different institutions and companies that were collaborators in the rest 46 trials.

According to Clinical.Site data, the most researched conditions in "Stanford University" are "Recessive Dystrophic Epidermolysis Bullosa" (6 trials), "Dystrophic Epidermolysis Bullosa" (3 trials), "DEB - Dystrophic Epidermolysis Bullosa" (2 trials), "Dominant Dystrophic Epidermolysis Bullosa" (2 trials) and "Epidermolysis Bullosa" (2 trials). Many other conditions were trialed in "Stanford University" in a lesser frequency.

Most popular intervention types in "Stanford University" are "Drug" (18 trials), "Other" (9 trials), "Device" (7 trials), "Procedure" (5 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "PTR-01" (3 trials), "0.9% nitroglycerin in TAM cream" (1 trials), "Abatacept" (1 trials) and "Acceptance and Commitment Therapy (ACT)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Stanford University" are 48 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are 27 active trials in "Stanford University". 3 are not yet recruiting, 20 are recruiting, 2 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 15 completed trials in Stanford University, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Stanford University, 4 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 14 trials that are defined as “Not Applicable".